After successful IPO, Quintiles plots 400 job cuts
Global CRO Quintiles is planning to slash 400 jobs this year, the company disclosed in a regulatory filing, primarily from its product development and healthcare services departments.
Nordion inks CMO deal with Navidea
Navidea Biopharmaceuticals has seen its fair share of CMO troubles, as problems with its last contract manufacturer delayed a much-anticipated FDA approval. Now, the diagnostics developer is hitching up with Nordion to manufacture an in-development imaging agent, hoping to avoid more production setbacks.
PRA winds up for IPO
Perhaps encouraged by the success of its North Carolina neighbor Quintiles, PRA is making moves toward an IPO of its own, filing a confidential draft registration form with the SEC.
PPD's BioDuro opens Shanghai discovery lab
BioDuro, PPD's China-based drug discovery business, has opened a state-of-the-art facility in Shanghai, a lab the company says will help it cozy up to clients in the growing Asian biopharmaceutical world.
Quintiles signs on to help Merck KGaA right the R&D ship
Amid repeated pipeline struggles and an R&D re-think, Merck KGaA has signed an exclusive deal with the newly public Quintiles, launching a novel collaboration that will give the CRO a seat at the decisionmaking table.
WuXi's revenue jumps 11.7% in strong Q1
WuXi PharmaTech, China's largest CRO, has big expectations for 2013, and the company is well on its way to following through, posting an 11.7% revenue jump in the first quarter.
Argentine CRO Stat Research taps Datatrak
Stat Research, a Buenos Aires-based CRO, has reached out to eClinical provider Datatrak in an effort to reduce clinical trial costs and accelerate drug development timelines.
GSK signs up with DKSH to tap Hong Kong market
GlaxoSmithKline is turning to market-expansion contractors DKSH to push its antibiotic products in Hong Kong, part of the drugmaker's efforts to cash in on booming Asian demand.
PRA boosts informatics with Welsh expansion
PRA has cut the ribbon on a new facility in Wales, planning to add about 100 new jobs in its informatics unit with help from the local government.
Harlan Labs doubles in specialty research with U.S. expansion
Harlan Laboratories is investing heavily in its Indiana and California facilities, bolstering specialty research by more than doubling its number of isolators.
AMRI piles on profits with strong Q2
AMRI's days of posting quarterly net losses appear to be far behind, as the company rode an 11% revenue jump to $6.5 million in net income, up from a negative $3.8 million in the same period last year.
Quintiles hauls in $947M IPO after upping offering
After months of rumor, vagary and anticipation, global CRO Quintiles is finally a public company, raising a total of $947 million after tendering more shares than initially planned.
Welsh CRO Simbec goes independent with new investment
CRO Simbec Research is using an investment from the Wales Life Sciences Investment Fund to acquire itself from the Canadian Altasciences Group, looking to expand its staff to more than 100 and chase new development deals around the world.
Charles River's income slides on flat sales
Charles River Labs saw its net profits decline about 2.3% last quarter, as risings costs negated 1.8% revenue growth.
CRO Novotech picks up PE investment to expand in Asia
Australia's Novotech has sold off a 30% stake to private equity firm Mercury Capital, planning to use the money to spread its reach across Asia.
TFS buys Beardsworth to expand oncology trial work
Swedish CRO TFS is getting back to M&A, acquiring Beardsworth Consulting Group to bolster its capacity for oncology and vaccine clinical trials.
Covance dials up projections after strong Q1
Covance posted 9.3% revenue growth and a 34.9% jump in profits last quarter, and now the CRO heavyweight is increasing its expectations for the full year.
Parexel buys Heron for $24M, brightens 2013 outlook
Parexel International is adding to its business and ticking up its forecast, buying consulting outfit Heron for $24 million and reporting another strong sales quarter.
Ergomed signs up to share costs, profits of Cel-Sci drug
In a novel deal, U.K. CRO Ergomed has hitched up with Cel-Sci for a Phase III trial of its head and neck cancer drug, but instead of just handling the study, Ergomed is putting up $30 million to fund development in exchange for single-digit royalties from the treatment.
AMRI inks 5-year CDMO deal with Ono
AMRI has locked down another 5-year partnership with Japan's Ono Pharmaceutical, agreeing to provide development and manufacturing services for the company's treatments, which include a promising multiple sclerosis drug.
